ライフサイエンスコーパス: cerulenin

1 esence of the fatty acid synthesis inhibitor cerulenin.

2 he addition of the FA biosynthesis inhibitor cerulenin.

3 and fasted wild-type mice, were treated with cerulenin.

4 ity of elongation reactions to inhibition by cerulenin.

5 o natural products, thiolactomycin (TLM) and cerulenin.

6 e superfamily, and the site of alkylation by cerulenin.

7 ed condensation reaction, was insensitive to cerulenin (100 microM) and cross-reacted with spinach KA

8 e have demonstrated that the natural product cerulenin ([2R,3S]-2,3-epoxy-4-oxo-7,10-trans,trans-dode

9 We examined the effects of the mycotoxin cerulenin (a covalent FAS inactivator), and the novel sm

10 Cerulenin, a FAS inhibitor, causes a similar biphasic ch

11 and carcinoma lines are growth inhibited by cerulenin, a noncompetitive inhibitor of fatty acid synt

12 yond C10 following treatment with 10 microns cerulenin, a potent inhibitor of KAS I.

13 The inhibition of FASN by cerulenin, a small molecule antibiotic, blocked cellular

14 We also found that cerulenin, a specific inhibitor of DIF-1 biosynthesis, a

15 FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands

16 ith the beta-ketoacyl-ACP synthase inhibitor cerulenin also blocked acylation.

17 Injection with cerulenin also decreased Fos immunoreactivity in the gra

18 A fadR strain was hypersensitive to cerulenin, an antibiotic that at low concentrations spec

19 tures are also smaller in cells treated with cerulenin, an inhibitor of de novo fatty acid synthesis

20 In the presence of cerulenin, an inhibitor of de novo fatty acid synthesis,

21 medium containing dextrose, oleic acid, and cerulenin, an inhibitor of fatty acid synthesis.

22 te elongation was 85% inhibited by 50 microm cerulenin, an inhibitor of ketoacyl-acyl carrier protein

23 Expression of each marker is inhibited by cerulenin, an inhibitor of polyketide synthesis, and can

24 Cerulenin, an inhibitor of the key fatty acid elongation

25 As or the fatty acid biosynthesis inhibitors cerulenin and 5-(tetradecyloxy)-2-furoic acid.

26 ed growth in YPD medium containing 25 microM cerulenin and 500 microM fatty acid (myristate (C14:0),

27 Cerulenin and a related compound, C75, have recently bee

28 e with fatty acid synthase (FAS) inhibitors (cerulenin and a synthetic compound C75) led to inhibitio

29 In addition, cerulenin and C75 dramatically attenuate IE and early ly

30 Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) onco

31 Antiestrogenic effects of cerulenin and C75 were observed by dose-dependent inhibi

32 Two specific FAS inhibitors, cerulenin and C75, prevent R activation of IE (Z) and ea

33 In contrast, cerulenin and diazoborine, specific inhibitors of fatty

34 The subtle differences between the FabB-cerulenin and FabF-cerulenin structures explain the diff

35 tment with the fatty acid synthase inhibitor cerulenin and is rescued by addition of exogenous unsatu

36 e catabolic effects associated with feeding, cerulenin and leptin.

37 ds and the labeling of ACP were inhibited by cerulenin and required ATP and Mg2+.

38 ynthase (FAS), including the natural product cerulenin and the novel compound c75, are selectively cy

39 ynthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are sele

40 75 based on the known mechanism of action of cerulenin and the theoretical reaction intermediates of

41 oth enzymes were sensitive to KAS inhibitors cerulenin and thiolactomycin.

42 growth of fat1Delta cells in the presence of cerulenin and under hypoxic conditions.

43 antly by dimethyl itaconate, C75, haloxyfop, cerulenin, and 1,2-cyclohexanedione.

44 To rule out non-FAS cerulenin- and C75-related effects, we finally monitored

45 Cerulenin, another drug that inhibits palmitoylation, al

46 the mycothiol S-conjugate of the antibiotic cerulenin as a substrate for Mca.

47 nder seed extracts was strongly inhibited by cerulenin at concentrations as low as 10 microM.

48 solution structures of the FabB-TLM and FabB-cerulenin binary complexes were determined.

49 Cerulenin binding mimics the condensation transition sta

50 mportance of the two His residues in TLM and cerulenin binding.

51 More than 30 analogues of cerulenin, both aromatic and aliphatic, with various cha

52 lished ascites tumor; and (e) treatment with cerulenin causes reduction in ascites incidence, delay i

53 etworks and differential network analyses on cerulenin, chlorpromazine, ethionamide, ofloxacin, thiol

54 The present studies demonstrate that cerulenin cytotoxicity is mediated by fatty acid pathway

55 e, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid st

56 However, in contrast to leptin, cerulenin did not prevent effects of fasting on plasma c

57 about 30% (P<0.05), further suggesting that cerulenin does not non-specifically activate wide variet

58 rescues DNA synthesis/S phase progression in cerulenin-exposed cells.

59 In contrast, injection with cerulenin had no grossly observable effects on cortical

60 Therefore, cerulenin has no deleterious effect on the L-type Ca(2+)

61 In the presence of the KAS I inhibitor cerulenin, however, transgenic seed extracts extended 6:

62 sensitive to thiolactomycin and resistant to cerulenin in an in vitro assay.

63 administration of the FAS inhibitors C75 and cerulenin in rats.

64 y acid synthase was inhibited with 45 microm cerulenin in the presence of 100 microm oleate (C(18:1))

65 C75 and cerulenin increased phosphorylation of S6K1 and S6, and

66 The protein acylation inhibitor cerulenin inhibited both phases of glucose-stimulated in

67 f pea H protein was inhibited by addition of cerulenin into the assay medium.

68 ns or when the fatty-acid synthase inhibitor cerulenin is included in the growth media.

69 The mechanism of DNA synthesis inhibition by cerulenin is indirect, because expression of certain vir

70 t studies have shown that the FAS inhibitor, cerulenin, is selectively cytotoxic to cell lines derive

71 (3)H-cerulenin labeling of the various Act KS mutant proteins

72 Injection with cerulenin, like feeding and leptin, also increased Fos i

73 the specific fatty acid synthase inhibitor, cerulenin, markedly reduces tumor cell fatty acid biosyn

74 C75 and cerulenin modulate AMPK phosphorylation and activity.

75 Conjugates of mycothiol with the antibiotic cerulenin, N-ethylmaleimide, 3-(N-maleimidopropionyl)-bi

76 contrast, the fatty-acid synthase inhibitor cerulenin nearly completely blocked sphingoid base produ

77 age was taken of this to study the effect of cerulenin on the K(ATP) channel-independent pathway of g

78 Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activati

79 entiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively activ

80 Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-A

81 harmacological inhibition of FAS activity by cerulenin or the novel compound C75.

82 -altering inhibitor of fatty acid synthesis (cerulenin), or an inhibitor of intracellular membrane tr

83 s a correlation between growth on fatty acid/cerulenin plates, the levels of fatty acid accumulation,

84 In the presence of KCl and diazoxide, cerulenin powerfully inhibited the augmentation of insul

85 increased metabolic rate in ob/ob mice, and cerulenin produced the same effects in wild-type mice, w

86 These data demonstrate that cerulenin produces metabolic effects similar to effects

87 Like leptin, cerulenin reduced body weight and food intake and increa

88 These results implicate cerulenin-resistant condensing activity in production of

89 ilis resting cells whereas a strain having a cerulenin-resistant FabF mutant produced more biotin.

90 nsitive to the fatty acid synthase inhibitor cerulenin, showed aberrant expression of fatty acid bios

91 esis with 5-(tetradecyloxy)-2-furoic acid or cerulenin significantly attenuates the enhancement of HC

92 ferences between the FabB-cerulenin and FabF-cerulenin structures explain the differences in the sens

93 Tsc13p-GFP into NV junctions is perturbed by cerulenin, suggesting that its binding to Nvj1p depends

94 eatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation

95 In contrast to two agents, C75 and cerulenin, that are widely used as inhibitors of mammali

96 on of the fatty acid biosynthesis inhibitor, cerulenin, that possesses an alkyl chain length in the r

97 inhibit fatty acid oxidation is affected by cerulenin, these data suggest that protein acylation is

98 lic acid fully restored biotin production in cerulenin-treated cells.

99 Here, we report that cerulenin treatment of human breast cancer cells inhibit

100 tty acid biosynthesis (FAB), since following cerulenin treatment, wild-type and relA strains expresse

101 Also, in contrast to leptin, cerulenin was highly effective to reduce body weight in

102 for growth under hypoxic conditions and when cerulenin was included in the culture media in the prese

103 ected with the fatty acid synthase inhibitor cerulenin were examined for Fos (a marker for neuronal a

104 The pharmacological agents H89 and cerulenin, which are inhibitors of endoplasmic reticulum

105 d mass/cell) but retain their sensitivity to cerulenin, which is reversed by 3-fold excess oleate sup

106 medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major pro

107 inishes, and the cells become insensitive to cerulenin while acquiring a differentiated, macrophage-l